Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 7;14:1148317. doi: 10.3389/fimmu.2023.1148317

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Rohila, Park, Pham, Jones, Tapia, Liu, Tamayo, Yu, Sharabi and Joshi

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Syk inhibition synergizes with checkpoint blockade to enhance anti-tumor immune responses in small neuroblastoma tumors. (A) Select pseudo-color plots (left panel) and quantification (right panel) of PDL1 in CD45- tumor cells and CD11b+F4/80+ TAMs from vehicle and R788-treated NB9464 tumors. ns, not significant. *p < 0.05. (B) NB9464 tumors were implanted into C57 BL/6 mice and treated with different inhibitors according to the depicted schema. (C) Tumor volume of NB9464 tumors implanted in C57BL/6 WT mice treated with either R788 or PDL1 or in combination, as shown in (B). (D) Kaplan Meir survival curves of mice treated with R788 and anti-PDL1 mAb. (E) Schema showing the strategy to rechallenge the cured mice. (F) Tumor volume of NB9464 tumors implanted in naïve C57BL/6 mice (n = 6) and cured mice (n = 4) from Figure (C) **** p < 0.0001.